[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI1006794A2 - Processo para preparar inibidores jak e compostos intermediários relacionados - Google Patents

Processo para preparar inibidores jak e compostos intermediários relacionados

Info

Publication number
BRPI1006794A2
BRPI1006794A2 BRPI1006794-9A BRPI1006794A BRPI1006794A2 BR PI1006794 A2 BRPI1006794 A2 BR PI1006794A2 BR PI1006794 A BRPI1006794 A BR PI1006794A BR PI1006794 A2 BRPI1006794 A2 BR PI1006794A2
Authority
BR
Brazil
Prior art keywords
intermediate compounds
jak inhibitors
related intermediate
preparing jak
preparing
Prior art date
Application number
BRPI1006794-9A
Other languages
English (en)
Inventor
Jiacheng Zhou
Pingli Liu
Qiyan Lin
Brian W Metcalf
David Meloni
Yongchun Pan
Michael Xia
Mei Li
Tai-Yuen Yue
James D Rodgers
Haisheng Wang
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Priority to BR122020005540A priority Critical patent/BR122020005540B8/pt
Priority to BR122020005528-6A priority patent/BR122020005528B1/pt
Publication of BRPI1006794A2 publication Critical patent/BRPI1006794A2/pt
Publication of BRPI1006794A8 publication Critical patent/BRPI1006794A8/pt
Publication of BRPI1006794B1 publication Critical patent/BRPI1006794B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/0825—Preparations of compounds not comprising Si-Si or Si-cyano linkages
    • C07F7/083—Syntheses without formation of a Si-C bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
BRPI1006794-9A 2009-01-15 2010-01-14 Processos para preparar inibidores jak BRPI1006794B1 (pt)

Priority Applications (2)

Application Number Priority Date Filing Date Title
BR122020005540A BR122020005540B8 (pt) 2009-01-15 2010-01-14 processos para preparar composições de inibidores jak
BR122020005528-6A BR122020005528B1 (pt) 2009-01-15 2010-01-14 Processos para preparar composições compreendendo inibidores jak

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14499109P 2009-01-15 2009-01-15
US61/144,991 2009-01-15
PCT/US2010/021003 WO2010083283A2 (en) 2009-01-15 2010-01-14 Processes for preparing jak inhibitors and related intermediate compounds

Publications (3)

Publication Number Publication Date
BRPI1006794A2 true BRPI1006794A2 (pt) 2015-08-25
BRPI1006794A8 BRPI1006794A8 (pt) 2017-07-11
BRPI1006794B1 BRPI1006794B1 (pt) 2022-05-17

Family

ID=42026219

Family Applications (3)

Application Number Title Priority Date Filing Date
BR122020005528-6A BR122020005528B1 (pt) 2009-01-15 2010-01-14 Processos para preparar composições compreendendo inibidores jak
BR122020005540A BR122020005540B8 (pt) 2009-01-15 2010-01-14 processos para preparar composições de inibidores jak
BRPI1006794-9A BRPI1006794B1 (pt) 2009-01-15 2010-01-14 Processos para preparar inibidores jak

Family Applications Before (2)

Application Number Title Priority Date Filing Date
BR122020005528-6A BR122020005528B1 (pt) 2009-01-15 2010-01-14 Processos para preparar composições compreendendo inibidores jak
BR122020005540A BR122020005540B8 (pt) 2009-01-15 2010-01-14 processos para preparar composições de inibidores jak

Country Status (29)

Country Link
US (9) US8410265B2 (pt)
EP (2) EP2398774B1 (pt)
JP (6) JP5650662B2 (pt)
KR (7) KR101824742B1 (pt)
CN (4) CN102348693B (pt)
AR (2) AR082747A1 (pt)
AU (5) AU2010204772B2 (pt)
BR (3) BR122020005528B1 (pt)
CA (2) CA3121743A1 (pt)
CL (3) CL2011001668A1 (pt)
CO (1) CO6400137A2 (pt)
EA (3) EA201991779A3 (pt)
EC (1) ECSP11011268A (pt)
ES (1) ES2641761T3 (pt)
IL (7) IL214061A (pt)
JO (3) JOP20190231A1 (pt)
MA (1) MA33038B1 (pt)
MX (5) MX2011007102A (pt)
MY (3) MY182004A (pt)
NZ (5) NZ706894A (pt)
PE (4) PE20110858A1 (pt)
PH (1) PH12016502060A1 (pt)
PL (1) PL2398774T3 (pt)
PT (1) PT2398774T (pt)
SG (3) SG172468A1 (pt)
TN (1) TN2011000329A1 (pt)
TW (7) TWI710562B (pt)
WO (1) WO2010083283A2 (pt)
ZA (1) ZA201104909B (pt)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060106020A1 (en) * 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
PL2455382T3 (pl) * 2005-12-13 2017-04-28 Incyte Holdings Corporation Podstawione heteroarylem pirolo[2,3-b]pirydyny i pirolo[2,3-b]pirymidyny jako inhibitory kinazy Janusowej
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
DK3070090T3 (en) 2007-06-13 2019-03-18 Incyte Holdings Corp USE OF SALTS OF THE JANUS-KINASE INHIBITOR (R) -3- (4- (7H-PYRROLO [2,3-D] PYRIMIDIN-4-YL) -1H-PYRAZOL-1-YL) -3- CYCLOPENTYL PROPANNITRIL
JP5480813B2 (ja) * 2007-11-16 2014-04-23 インサイト・コーポレイション Ｊａｎｕｓキナーゼ阻害剤としての置換複素環
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
JOP20190231A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
AR076794A1 (es) * 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
KR20120030447A (ko) 2009-05-22 2012-03-28 인사이트 코포레이션 Ｊａｋ 저해물질로서 ３-［４-（７ｈ-피롤로［２,３-ｄ］피리미딘-４-일）-１ｈ-피라졸-１-일］옥탄- 또는 헵탄-니트릴
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CA2777114C (en) * 2009-10-09 2018-10-23 Incyte Corporation Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
CN102844317B (zh) * 2010-02-18 2015-06-03 因西特公司 作为Janus激酶抑制剂的环丁烷和甲基环丁烷衍生物
RS54823B1 (sr) 2010-03-10 2016-10-31 Incyte Holdings Corp Derivati piperidin-4-il azetidina kao inhibitori jak1
NZ603446A (en) 2010-04-14 2014-05-30 Array Biopharma Inc 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases
CA2799928C (en) 2010-05-21 2020-03-31 Incyte Corporation Topical formulation for a jak inhibitor
EA026201B1 (ru) 2010-11-19 2017-03-31 Инсайт Холдингс Корпорейшн Циклобутилзамещенные производные пирролопиридина и пирролопиримидина как ингибиторы jak
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
EP2675451B9 (en) 2011-02-18 2017-07-26 Novartis Pharma AG mTOR/JAK INHIBITOR COMBINATION THERAPY
CN102690281A (zh) * 2011-03-22 2012-09-26 上海药明康德新药开发有限公司 1-甲基4-吡唑频哪醇酯的合成方法
KR20140040819A (ko) 2011-06-20 2014-04-03 인사이트 코포레이션 Ｊａｋ 저해제로서의 아제티디닐 페닐, 피리딜 또는 피라지닐 카르복스아미드 유도체
CA2844507A1 (en) 2011-08-10 2013-02-14 Novartis Pharma Ag Jak pi3k/mtor combination therapy
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
WO2013157021A1 (en) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
SI3495367T1 (sl) 2012-06-13 2021-01-29 Incyte Holdings Corporation Substituirane triciklične spojine kot zaviralci FGFR
EP2861600A1 (en) 2012-06-15 2015-04-22 Concert Pharmaceuticals Inc. Deuterated derivatives of ruxolitinib
WO2014011540A1 (en) 2012-07-09 2014-01-16 Emory University Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
ES2717279T3 (es) 2012-08-17 2019-06-20 Concert Pharmaceuticals Inc Baricitinib deuterada
WO2014060381A1 (de) 2012-10-18 2014-04-24 Bayer Cropscience Ag Heterocyclische verbindungen als schädlingsbekämpfungsmittel
JP2016503395A (ja) 2012-10-31 2016-02-04 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 病害生物防除剤としての複素環化合物
MX2015005428A (es) 2012-11-01 2015-07-21 Incyte Corp Derivados triciclicos fusionados de tiofeno como inhibidores de la cinasa janus (jak).
CN113384546A (zh) 2012-11-15 2021-09-14 因赛特公司 鲁索利替尼的缓释剂型
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
UA121532C2 (uk) 2013-03-06 2020-06-10 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки при отриманні інгібітора jak
JP6449244B2 (ja) 2013-04-19 2019-01-09 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｆｇｆｒ抑制剤としての二環式複素環
EP3527263B1 (en) 2013-05-17 2020-10-28 Incyte Corporation Bipyrazole derivatives as jak inhibitors
MY195091A (en) 2013-08-07 2023-01-10 Incyte Corp Sustained Release Dosage Forms for a JAK1 Inhibitor
CN103601749B (zh) * 2013-11-26 2016-04-27 大连联化化学有限公司 一种1-烷基吡唑-4-硼酸频哪醇酯的合成方法
HUE054560T2 (hu) 2013-12-05 2021-09-28 Pfizer Pirrolo[2,3-d]pirimidinil, pirrolo[2,3-b]pirazinil és pirrolo[2,3-d]piridinil akrilamidok
CN104860950A (zh) * 2014-02-24 2015-08-26 重庆医药工业研究院有限责任公司 一种制备4-氯吡咯[2,3-d]并嘧啶的方法
NZ763326A (en) 2014-04-08 2023-04-28 Incyte Holdings Corp Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
US9802957B2 (en) 2014-04-30 2017-10-31 Incyte Corporation Processes of preparing a JAK1 inhibitor and new forms thereto
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
CN105218548A (zh) * 2014-06-09 2016-01-06 上海海和药物研究开发有限公司 一种新型杂环化合物及其制备方法和作为激酶抑制剂的用途
LT3179991T (lt) 2014-08-11 2021-11-10 Acerta Pharma B.V. Terapiniai btk inhibitoriaus ir bcl-2 inhibitoriaus deriniai
US20170224819A1 (en) 2014-08-11 2017-08-10 Acerta Pharma B.V. Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor
HRP20220738T1 (hr) 2014-08-11 2022-08-19 Acerta Pharma B.V. Terapijske kombinacije inhibitora btk, inhibitora pd-1 i/ili inhibitora pd-l1
WO2016035014A1 (en) * 2014-09-01 2016-03-10 Sun Pharmaceutical Industries Limited Processes for the preparation of ruxolitinib phosphate
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CZ2014773A3 (cs) * 2014-11-10 2016-05-18 Zentiva, K.S. Soli (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu
CN104496904B (zh) * 2014-11-28 2017-01-11 上海北卡医药技术有限公司 一种鲁索利替尼中间体的合成方法
EP3227298A4 (en) * 2014-12-05 2018-05-23 Sun Pharmaceutical Industries Ltd Process for the preparation of baricitinib and an intermediate thereof
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AU2016219822B2 (en) 2015-02-20 2020-07-09 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CZ2015496A3 (cs) 2015-07-14 2017-01-25 Zentiva, K.S. Krystalické formy solí (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu a jejich příprava
CN106397443A (zh) * 2015-07-17 2017-02-15 浙江九洲药业股份有限公司 一种吡咯嘧啶类衍生物中间体的制备方法
HU230805B1 (hu) * 2015-12-23 2018-06-28 Egis Gyógyszergyár Zrt Eljárás és köztitermék baricitinib előállítására
WO2017114461A1 (zh) 2015-12-31 2017-07-06 正大天晴药业集团股份有限公司 一种芦可替尼的合成工艺
CZ201629A3 (cs) 2016-01-22 2017-08-02 Zentiva, K.S. Krystalické modifikace solí (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu a způsoby jejich přípravy
US10822339B2 (en) * 2016-01-26 2020-11-03 Hangzhou Huadong Medicine Group Biopharmaceutical Co. Ltd Pyrrolopyrimidine five-membered azacyclic derivative and application thereof
CN107226814A (zh) * 2016-03-23 2017-10-03 罗欣生物科技（上海）有限公司 一种巴瑞克替尼中间体的制备方法
EP3452039B1 (en) 2016-05-04 2024-07-03 Sun Pharmaceutical Industries, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
CN107513069A (zh) * 2016-06-16 2017-12-26 正大天晴药业集团股份有限公司 手性吡咯并嘧啶化合物的制备方法
CN106188116B (zh) * 2016-07-14 2018-02-06 沧州普瑞东方科技有限公司 一种合成吡唑‑4‑硼酸频那醇酯的方法
CN107722012B (zh) * 2016-08-11 2020-05-29 斯福瑞（南通）制药有限公司 制备4-氯-7H-吡咯并[2,3-d]嘧啶的方法
CN107759601B (zh) * 2016-08-23 2020-09-11 苏州旺山旺水生物医药有限公司 一种jak抑制剂及其盐的制备方法
CN107759623B (zh) * 2016-08-23 2020-08-14 苏州旺山旺水生物医药有限公司 Jak抑制剂的中间体及其制备方法
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN107501154B (zh) * 2017-09-13 2020-02-11 浙江普洛康裕制药有限公司 (s)-1-(2-氯乙酰基)吡咯烷-2-甲腈的合成方法
CN109651424B (zh) * 2017-10-11 2021-01-22 新发药业有限公司 一种7-保护基-4-(1-氢-吡唑-4-基)吡咯[2,3-d]嘧啶的合成方法
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
US10766900B2 (en) 2017-12-29 2020-09-08 Formosa Laboratories, Inc. Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof
UA127488C2 (uk) 2018-01-30 2023-09-06 Інсайт Корпорейшн Способи одержання (1-(3-фтор-2-(трифторметил)ізонікотиноїл)піперидин-4-ону)
IL311485A (en) 2018-02-16 2024-05-01 Incyte Corp JAK1 pathway inhibitors for the treatment of cytokine-related disorders
US11584961B2 (en) 2018-03-30 2023-02-21 Incyte Corporation Biomarkers for inflammatory skin disease
KR20210018203A (ko) 2018-03-30 2021-02-17 인사이트 코포레이션 Jak 억제제를 사용하는 화농성 한선염의 치료
WO2019200030A1 (en) 2018-04-13 2019-10-17 Incyte Corporation Biomarkers for graft-versus-host disease
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
EA202092649A1 (ru) 2018-05-04 2021-06-21 Инсайт Корпорейшн Соли ингибитора fgfr
KR102545594B1 (ko) 2018-07-31 2023-06-21 록쏘 온콜로지, 인코포레이티드 (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의 분무-건조된 분산물 및 제제
TWI808250B (zh) * 2018-09-04 2023-07-11 美商施萬生物製藥研發 Ip有限責任公司 用於製備jak抑制劑之方法及其中間體
WO2020072870A1 (en) 2018-10-05 2020-04-09 Johnson Matthey Public Limited Company Co-crystal forms of baricitinib
AU2019374072A1 (en) 2018-10-31 2021-05-27 Incyte Corporation Combination therapy for treatment of hematological diseases
WO2020131674A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
CN113490666A (zh) 2018-12-19 2021-10-08 奥瑞生物药品公司 作为fgfr酪氨酸激酶的抑制剂的取代的吡唑并[1,5-a]吡啶化合物
US20220306636A1 (en) * 2019-02-06 2022-09-29 Concert Pharmaceuticals, Inc. Process for preparing enantiomerically enriched jak inhibitors
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
CN110028509B (zh) * 2019-05-27 2020-10-09 上海勋和医药科技有限公司 作为选择性jak2抑制剂的吡咯并嘧啶类化合物、其合成方法及用途
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN110538183B (zh) * 2019-10-09 2021-05-04 吉林大学 一种预防和治疗小儿湿疹的组合物及其制备方法
AU2020366006A1 (en) 2019-10-14 2022-04-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
BR112022009710A2 (pt) 2019-11-22 2022-08-09 Incyte Corp Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
CN115151539A (zh) 2019-12-04 2022-10-04 因赛特公司 Fgfr抑制剂的衍生物
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
AR122505A1 (es) 2020-06-02 2022-09-14 Incyte Corp Procesos para preparar un inhibidor de jak1
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN111790439B (zh) * 2020-07-29 2022-12-27 成都能特科技发展有限公司 一种手性二级胺二苯基膦芳甲酰胺双功能催化剂及其制备方法与应用
CA3194469A1 (en) 2020-08-12 2022-02-17 Concert Pharmaceuticals, Inc. Process for preparing enantiomerically enriched jak inhibitors
CA3192055A1 (en) 2020-08-18 2022-02-24 Incyte Corporation Process and intermediates for preparing a jak1 inhibitor
IL300555A (en) 2020-08-18 2023-04-01 Incyte Corp Process and intermediates for preparing a JAK inhibitor
CA3196551A1 (en) 2020-10-28 2022-05-05 Sun Pharmaceutical Industries, Inc. Regimens for the treatment of hair loss disorders with deuterated jak inhibitors
IL303238A (en) 2020-12-08 2023-07-01 Incyte Corp Jak1 pathway inhibitors for the treatment of vitiligo
CN112625030A (zh) * 2020-12-25 2021-04-09 杭州澳赛诺生物科技有限公司 一种一锅法合成n-保护3-溴代吡唑的合成方法
CN114907353A (zh) * 2021-02-09 2022-08-16 明慧医药（杭州）有限公司 一种前药化合物及其制备方法和用途
CN112876503B (zh) * 2021-03-18 2022-04-29 中国科学院兰州化学物理研究所 用于癌症硼中子俘获治疗药物的硼酸盐化合物及其制备
CA3215903A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CN113292569A (zh) * 2021-05-25 2021-08-24 常州制药厂有限公司 一种jak抑制剂的制备方法
CN113264936B (zh) * 2021-05-25 2022-08-09 常州制药厂有限公司 一种jak抑制剂关键中间体及其制备方法
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
CN118317946A (zh) * 2021-07-12 2024-07-09 因赛特公司 用于制备巴瑞替尼的方法和中间体
IL309840A (en) * 2021-07-20 2024-02-01 Coval Biopharma Shanghai Co Ltd An external antidialectic coupling compound drug, and a method of preparation therefor and use thereof
WO2023018904A1 (en) 2021-08-11 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
CA3228509A1 (en) 2021-08-12 2023-02-16 Sun Pharmaceutical Industries, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
WO2023042224A1 (en) * 2021-09-18 2023-03-23 Natco Pharma Limited An improved process for the preparation of ruxolitinib phosphate
CN114044777B (zh) * 2022-01-10 2022-04-19 南京佰麦生物技术有限公司 一种磷酸芦可替尼的制备方法
WO2023215520A1 (en) 2022-05-04 2023-11-09 Sun Pharmaceutical Industries, Inc. Dosage regimens for treatment with deuterated jak inhibitors
WO2023223253A1 (en) * 2022-05-19 2023-11-23 Glenmark Life Sciences Limited Process for preparation of ruxolitinib
CN114805368B (zh) * 2022-05-25 2023-12-01 山东诺明康药物研究院有限公司 一种芦克替尼的制备方法
CN115028638A (zh) * 2022-06-09 2022-09-09 安徽大学 一种鲁索替尼中间体的制备方法
CN117384163A (zh) * 2022-07-05 2024-01-12 盛世泰科生物医药技术(苏州)股份有限公司 一种含偕二氟基的化合物及其制备方法和用途
US20240166654A1 (en) * 2022-11-11 2024-05-23 Zhejiang Ausun Pharmaceutical Co., Ltd. Ruxolitinib crystal and pharmaceutical composition thereof

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2985589A (en) 1957-05-22 1961-05-23 Universal Oil Prod Co Continuous sorption process employing fixed bed of sorbent and moving inlets and outlets
JPS5519438A (en) 1978-07-26 1980-02-12 Mitsubishi Electric Corp Brazing method
US4402832A (en) 1982-08-12 1983-09-06 Uop Inc. High efficiency continuous separation process
US4498991A (en) 1984-06-18 1985-02-12 Uop Inc. Serial flow continuous separation process
JP2513001B2 (ja) * 1988-11-01 1996-07-03 山川薬品工業株式会社 光学活性テトラヒドロフラン−２−カルボン酸のラセミ化方法
DE4038356A1 (de) * 1990-12-01 1992-06-04 Bayer Ag Verfahren zur racemisierung von optisch aktiven l-aryl-alkylaminen
JPH04308556A (ja) * 1991-04-05 1992-10-30 Hokuriku Seiyaku Co Ltd 光学活性なベンジルアルコール誘導体のラセミ化方法
JPH06122686A (ja) * 1992-10-12 1994-05-06 Fujisawa Pharmaceut Co Ltd ラセミ体の光学分割法
JPH07247286A (ja) * 1994-01-18 1995-09-26 Sankyo Co Ltd 含窒素環状化合物の光学分割方法
US5630943A (en) 1995-11-30 1997-05-20 Merck Patent Gesellschaft Mit Beschrankter Haftung Discontinuous countercurrent chromatographic process and apparatus
GB9602516D0 (en) * 1996-02-08 1996-04-10 Chiroscience Ltd Racemisation
US6063284A (en) 1997-05-15 2000-05-16 Em Industries, Inc. Single column closed-loop recycling with periodic intra-profile injection
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
FR2785196B1 (fr) 1998-10-29 2000-12-15 Inst Francais Du Petrole Procede et dispositif de separation avec des zones chromatographiques a longueur variable
US6375839B1 (en) 1998-10-29 2002-04-23 Institut Francais Du Petrole Process and device for separation with variable-length chromatographic zones
US6413419B1 (en) 1998-10-29 2002-07-02 Institut Francais Du Petrole Process and device for separation with variable-length chromatographic
JP4078074B2 (ja) 1999-12-10 2008-04-23 ファイザー・プロダクツ・インク ピロロ［２，３−ｄ］ピリミジン化合物
BR0115306B1 (pt) * 2000-11-17 2013-12-24 Takeda Pharmaceutical Derivado de imidazol, composição farmacêutica, métodos para a produção de um derivado de imidazol e de um composto oticamente ativo de um derivado de imidazol ou de um seu sal farmaceuticamente aceitável, composto, sal, e, sal diastereomérico
IL164209A0 (en) * 2002-05-31 2005-12-18 Eisai Co Ltd Pyrazole derivatives and pharmaceutical compositions containing the same
WO2004013141A1 (en) 2002-08-06 2004-02-12 Astrazeneca Ab Condensed pyridines and pyrimidines with tie2 (tek) activity
JP2004143053A (ja) * 2002-10-22 2004-05-20 Senju Pharmaceut Co Ltd β−アミノヒドロキサム酸誘導体およびその用途
SI1587821T1 (sl) 2002-12-19 2009-02-28 Scripps Research Inst Sestavki in postopki za stabiliziranje transtiretina in zaviranje napaäśnega zvijanja transtiretina
JP2005304368A (ja) * 2004-04-21 2005-11-04 Toyo Kasei Kogyo Co Ltd 光学活性な４−（ｎ−保護アミノ）−１−アルケン−３−オールの製造方法、およびそれを用いた３−ベンザミド−２−ヒドロキシカルボン酸またはその塩の製造方法
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
CA2573362A1 (en) * 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
ES2320487T3 (es) 2005-02-03 2009-05-22 Vertex Pharmaceuticals, Inc. Pirrolopirimidinas utiles como inhibidores de proteina quinasas.
EP1926735A1 (en) 2005-09-22 2008-06-04 Incyte Corporation Tetracyclic inhibitors of janus kinases
AU2006300182B2 (en) 2005-10-14 2012-01-19 Sumitomo Chemical Company, Limited Hydrazide compound and pesticidal use of the same
US20130137681A1 (en) 2005-12-13 2013-05-30 Incyte Corporation HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS
PL2455382T3 (pl) 2005-12-13 2017-04-28 Incyte Holdings Corporation Podstawione heteroarylem pirolo[2,3-b]pirydyny i pirolo[2,3-b]pirymidyny jako inhibitory kinazy Janusowej
KR100815432B1 (ko) * 2005-12-29 2008-03-20 엘아이지엔설팅주식회사 사업 재난 관리 시스템, 방법, 및 상기 방법을 실행시키기위한 컴퓨터 판독 가능한 프로그램을 기록한 매체
EP2001884A1 (en) 2006-04-05 2008-12-17 Vertex Pharmaceuticals, Inc. Deazapurines useful as inhibitors of janus kinases
DE102006016426A1 (de) * 2006-04-07 2007-10-11 Merck Patent Gmbh Neuartige Cyclobutyl-Verbindungen als Kinase-Inhibitoren
NL2000613C2 (nl) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
WO2008013622A2 (en) 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
ME02372B (me) * 2006-11-22 2016-06-20 Incyte Holdings Corp Imidazotriazini i imidazopiramidini kao inhibitori kinaze
AR064416A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
US8513270B2 (en) 2006-12-22 2013-08-20 Incyte Corporation Substituted heterocycles as Janus kinase inhibitors
KR20080062876A (ko) 2006-12-29 2008-07-03 주식회사 대웅제약 신규한 항진균성 트리아졸 유도체
GB0704932D0 (en) * 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
EA200901157A1 (ru) * 2007-04-10 2010-04-30 ЭсДжиИкс ФАРМАСЬЮТИКАЛЗ, ИНК. Конденсированные кольцевые гетероциклические модуляторы киназы
DK3070090T3 (en) 2007-06-13 2019-03-18 Incyte Holdings Corp USE OF SALTS OF THE JANUS-KINASE INHIBITOR (R) -3- (4- (7H-PYRROLO [2,3-D] PYRIMIDIN-4-YL) -1H-PYRAZOL-1-YL) -3- CYCLOPENTYL PROPANNITRIL
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
AR067354A1 (es) * 2007-06-29 2009-10-07 Sunesis Pharmaceuticals Inc Compuestos utiles como inhibidores de la raf quinasa
JP5480813B2 (ja) 2007-11-16 2014-04-23 インサイト・コーポレイション Ｊａｎｕｓキナーゼ阻害剤としての置換複素環
MX2010010012A (es) 2008-03-11 2010-10-20 Incyte Corp Derivados de azetidina y ciclobutano como inhibidores de jak.
PT2297042E (pt) * 2008-03-19 2013-10-10 Bial Portela & Ca Sa Hidrogenação catalítica assimétrica
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
JOP20190231A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
IT1393787B1 (it) 2009-03-30 2012-05-08 Cps Color Equipment Spa Dispositivo di erogazione di prodotti fluidi e relativo procedimento di erogazione
AR076794A1 (es) 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
KR20120030447A (ko) 2009-05-22 2012-03-28 인사이트 코포레이션 Ｊａｋ 저해물질로서 ３-［４-（７ｈ-피롤로［２,３-ｄ］피리미딘-４-일）-１ｈ-피라졸-１-일］옥탄- 또는 헵탄-니트릴
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CA2777114C (en) 2009-10-09 2018-10-23 Incyte Corporation Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
CN102844317B (zh) 2010-02-18 2015-06-03 因西特公司 作为Janus激酶抑制剂的环丁烷和甲基环丁烷衍生物
RS54823B1 (sr) 2010-03-10 2016-10-31 Incyte Holdings Corp Derivati piperidin-4-il azetidina kao inhibitori jak1
CA2799928C (en) 2010-05-21 2020-03-31 Incyte Corporation Topical formulation for a jak inhibitor
EA026201B1 (ru) 2010-11-19 2017-03-31 Инсайт Холдингс Корпорейшн Циклобутилзамещенные производные пирролопиридина и пирролопиримидина как ингибиторы jak
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
EP2675451B9 (en) 2011-02-18 2017-07-26 Novartis Pharma AG mTOR/JAK INHIBITOR COMBINATION THERAPY
KR20140040819A (ko) 2011-06-20 2014-04-03 인사이트 코포레이션 Ｊａｋ 저해제로서의 아제티디닐 페닐, 피리딜 또는 피라지닐 카르복스아미드 유도체
CA2844507A1 (en) 2011-08-10 2013-02-14 Novartis Pharma Ag Jak pi3k/mtor combination therapy
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak

Also Published As

Publication number Publication date
AU2020201709A1 (en) 2020-03-26
EP3272738A3 (en) 2018-04-04
EA034207B1 (ru) 2020-01-16
KR20190083010A (ko) 2019-07-10
MX349632B (es) 2017-08-07
CL2011001668A1 (es) 2012-02-03
EP3272738A2 (en) 2018-01-24
JP2015091805A (ja) 2015-05-14
JP6843955B2 (ja) 2021-03-17
CA2749483A1 (en) 2010-07-22
BR122020005540B8 (pt) 2021-07-27
KR101824742B1 (ko) 2018-02-01
MA33038B1 (fr) 2012-02-01
BR122020005540B1 (pt) 2021-03-02
IL214061A0 (en) 2011-08-31
US20130253193A1 (en) 2013-09-26
EP2398774A2 (en) 2011-12-28
ZA201104909B (en) 2018-11-28
US20150218174A1 (en) 2015-08-06
US20100190981A1 (en) 2010-07-29
AU2018202625B2 (en) 2019-12-12
KR101999933B1 (ko) 2019-07-12
US10975085B2 (en) 2021-04-13
TN2011000329A1 (en) 2013-03-27
AU2010204772B2 (en) 2016-05-26
NZ594057A (en) 2013-11-29
TW201038575A (en) 2010-11-01
CN105669675A (zh) 2016-06-15
US20180237442A1 (en) 2018-08-23
JP2012515212A (ja) 2012-07-05
NZ706894A (en) 2016-11-25
TW201936608A (zh) 2019-09-16
TW202003521A (zh) 2020-01-16
TWI814080B (zh) 2023-09-01
BR122020005528B1 (pt) 2022-05-17
US20210253584A1 (en) 2021-08-19
KR20180011887A (ko) 2018-02-02
IL267122A (en) 2019-08-29
JO3441B1 (ar) 2019-10-20
JP2019048835A (ja) 2019-03-28
SG10201913261QA (en) 2020-03-30
TWI710562B (zh) 2020-11-21
CN102348693B (zh) 2016-03-16
KR20210130846A (ko) 2021-11-01
KR102318359B1 (ko) 2021-10-27
TWI644915B (zh) 2018-12-21
IL242750B (en) 2019-06-30
IL283038A (en) 2021-06-30
JP2021100930A (ja) 2021-07-08
JOP20190231A1 (ar) 2017-06-16
US9000161B2 (en) 2015-04-07
CL2013002617A1 (es) 2014-03-28
SG172468A1 (en) 2011-08-29
WO2010083283A2 (en) 2010-07-22
EA201991779A3 (ru) 2020-04-30
PT2398774T (pt) 2017-09-29
MX2011007102A (es) 2011-09-15
TW201718591A (zh) 2017-06-01
CN108395433B (zh) 2024-10-22
MY186533A (en) 2021-07-25
US20160257687A1 (en) 2016-09-08
TW201524982A (zh) 2015-07-01
PL2398774T3 (pl) 2017-11-30
IL274422A (en) 2020-06-30
EA020643B1 (ru) 2014-12-30
NZ617077A (en) 2015-05-29
US20200002341A1 (en) 2020-01-02
AR127757A2 (es) 2024-02-28
MX363976B (es) 2019-04-10
TWI740775B (zh) 2021-09-21
CA2749483C (en) 2021-07-27
TW202146417A (zh) 2021-12-16
IL242752A (en) 2017-06-29
AU2020201709B2 (en) 2021-12-09
US8410265B2 (en) 2013-04-02
CN105669676A (zh) 2016-06-15
PH12016502060B1 (en) 2017-09-18
JP5650662B2 (ja) 2015-01-07
NZ725585A (en) 2018-05-25
AR082747A1 (es) 2013-01-09
CN108395433A (zh) 2018-08-14
PH12016502060A1 (en) 2017-09-18
PE20171102A1 (es) 2017-08-07
CN105669676B (zh) 2018-04-24
EA201170935A1 (ru) 2012-02-28
US20130253190A1 (en) 2013-09-26
US20130253191A1 (en) 2013-09-26
CN102348693A (zh) 2012-02-08
BRPI1006794A8 (pt) 2017-07-11
AU2016216537A1 (en) 2016-09-01
EP2398774B1 (en) 2017-07-05
KR102138485B1 (ko) 2020-07-27
CA3121743A1 (en) 2010-07-22
PE20211639A1 (es) 2021-08-24
MX357874B (es) 2018-07-27
KR102220482B1 (ko) 2021-02-25
KR20220104280A (ko) 2022-07-26
US10364248B2 (en) 2019-07-30
CL2016000346A1 (es) 2016-11-25
NZ739757A (en) 2019-01-25
AU2016216537B2 (en) 2018-05-10
IL274422B (en) 2021-06-30
IL267122B (en) 2020-05-31
SG10201705183SA (en) 2017-07-28
EP3272738B1 (en) 2024-11-13
PE20160788A1 (es) 2016-09-04
JP6430464B2 (ja) 2018-11-28
JOP20190230A1 (ar) 2017-06-16
TWI720517B (zh) 2021-03-01
CO6400137A2 (es) 2012-03-15
AU2018202625A1 (en) 2018-05-10
AU2010204772A1 (en) 2011-08-04
MY163540A (en) 2017-09-15
IL214061A (en) 2017-06-29
EA201400575A1 (ru) 2015-02-27
KR102422043B1 (ko) 2022-07-18
US9290506B2 (en) 2016-03-22
ECSP11011268A (es) 2011-12-30
US8993582B2 (en) 2015-03-31
AU2022201630B2 (en) 2024-04-18
JP6630802B2 (ja) 2020-01-15
KR20110104119A (ko) 2011-09-21
MY182004A (en) 2021-01-18
ES2641761T3 (es) 2017-11-13
PE20110858A1 (es) 2011-12-04
JP6054355B2 (ja) 2016-12-27
WO2010083283A3 (en) 2010-10-14
JP2020073491A (ja) 2020-05-14
JP2017081934A (ja) 2017-05-18
KR20200095568A (ko) 2020-08-10
EA201991779A2 (ru) 2019-12-30
TWI462924B (zh) 2014-12-01
TW202118766A (zh) 2021-05-16
MX2019003989A (es) 2019-08-12
US8883806B2 (en) 2014-11-11
US9908888B2 (en) 2018-03-06
KR20210022770A (ko) 2021-03-03
TWI665200B (zh) 2019-07-11
BRPI1006794B1 (pt) 2022-05-17
AU2022201630A1 (en) 2022-03-31
IL242751B (en) 2018-03-29

Similar Documents

Publication Publication Date Title
BRPI1006794A2 (pt) Processo para preparar inibidores jak e compostos intermediários relacionados
BRPI1010766A2 (pt) processo para rebaudiosídeo d
BRPI1011743A2 (pt) processo para preparar poliéster insaturado
BRPI1010759A2 (pt) processo para produção de proteína
SMT201400100B (it) Processo migliorato
BR112012000822A2 (pt) processo
BR112012002335A2 (pt) pigmento composto e método para preparação do mesmo
BR112012012338A2 (pt) processo
BR112012014490A2 (pt) processo para a preparação substituída de 1-o-acil-2-desóxi-2-fluoro-4-tio-beta-d-arabinofuranoses
BRPI1012018A2 (pt) processo para preparar um composto
BRPI0816911A2 (pt) Processo para preparação de 4-aminobut-2-enolidas
BRPI1014267A2 (pt) processo para a carbonitrificação
BR112013016365A2 (pt) composição de lipossoma e processo para produção do mesmo
BRPI0921420A2 (pt) processo para preparar compostos
BRPI1013830A2 (pt) Processo para a iodação de compostos aromáticos
BR112012004604A2 (pt) processo para preparar de maneira contínua aromáticos nitrados
BRPI1007391A2 (pt) processo para o resfriamento controlado da troposfera
BR112012002500A2 (pt) Processo para o preparo de derivados de ácido 1- (2-halobifenil-4-yl) - ciclopropanocarboxílico
BRPI0917836A2 (pt) processo para preparar uretanos
BRPI1007573A2 (pt) processo
BRPI0813788A2 (pt) Processo para preparação de metacrilato de alila
BR112013014949A2 (pt) processo para produção de proteína
BRPI0911992A2 (pt) processo para preparação de bifenilanilidas substituídas
BR112012001731A2 (pt) Processo para a preparação de 1-benzil-3-hidroximetil-1h-indazol
BR112012003642A2 (pt) processo

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: INCYTE CORPORATION (US)

B25A Requested transfer of rights approved

Owner name: INCYTE HOLDINGS CORPORATION (US)

B25G Requested change of headquarter approved

Owner name: INCYTE HOLDINGS CORPORATION (US)

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B65X Notification of requirement for priority examination of patent application
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/01/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.